CD44 and neoplasm: Binding to several CD44 receptors by different HA chains attached to the same NP creates a sufficiently strong avidity for effective targeting and internalization [90]; (iii) selecting HA oligosaccharides which are sufficiently long to bind to more than a single CD44 receptor but too short to be bound by the HARE receptor in the liver (preferably <10 kDa), may facilitate the construction of an HA-based CD44-targeted nanocarrier that evades hepatic elimination but accomplishes passive targeting of the tumor, and selective active uptake into the tumor cells [87].